Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease

American Journal of Hypertension

Volumn 25, Issue 6, 2012, Pages 636-639

  Lizakowski, Sawomir ^a   Tylicki, Leszek ^a   Renke, Marcin ^a   Rutkowski, Przemysaw ^a   Heleniak, Zbigniew ^a   Sławińska Morawska, Maja ^a   Aleksandrowicz Wrona, Ewa ^a   Małgorzewicz, Sylwia ^a   Rutkowski, Bolesaw ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

ACE inhibitor; aliskiren; blood pressure; chronic kidney diseases; hypertension; procollagen III N terminal propeptide (PIIINP); transforming growth factor 1 (TGF 1)

Indexed keywords

ALISKIREN; CREATININE; PERINDOPRIL; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PRORENIN; RENIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; FEMALE; HISTOLOGY; HUMAN; HYPERTENSION; KIDNEY CONCENTRATING CAPACITY; KIDNEY FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; CREATININE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBROSIS; FUMARATES; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; PEPTIDE FRAGMENTS; PERINDOPRIL; PILOT PROJECTS; PROCOLLAGEN; RENIN; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84861183637     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.14     Document Type: Article

References (19)

1. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20: 587-597. (Pubitemid 46678721)
2. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69:1503-1506.
3. Gross O, Girgert R, Rubel D, Temme J, Theissen S, Müller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 2011; 24:355-361.
4. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50:2398-2404. (Pubitemid 47512400)
5. Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, Wu MJ. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol 2010; 299:F929-F941.
6. Tylicki L, Larczynski W, Rutkowski B. Renal protective effects of the reninangiotensin-aldosterone system blockade: from evidence-based approach to perspectives. Kidney Blood Press Res 2005; 28:230-242. (Pubitemid 43048613)
7. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97:7667-7669. (Pubitemid 30460701)
8. Eddy AA, Neilson EG. Chronic kidney disease progression. J Am Soc Nephrol 2006; 17:2964-2966. (Pubitemid 44707755)
9. Böttinger EP. TGF-beta in renal injury and disease. Semin Nephrol 2007; 27:309-320.
10. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74:991-1003. (Pubitemid 26182412)
11. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31:181-188.
12. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346:371-374.
13. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G, Cooper ME. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998; 47:414-422. (Pubitemid 28104204)
14. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446. (Pubitemid 351793017)
15. Danser AH. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? Hypertens Res 2010; 33:4-10.
16. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69:105-113. (Pubitemid 43117745)
17. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61:1461-1468. (Pubitemid 47228610)
18. Schefe JH, Unger T, Funke-Kaiser H. PLZF and the (pro)renin receptor. J Mol Med 2008; 86:623-627.
19. Ferri N, Greco CM, Maiocchi G, Corsini A. Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. J Renin Angiotensin Aldosterone Syst 2011; 12:469-474.